Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage.

@article{Porter1989DesferrioxamineOE,
  title={Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage.},
  author={John B. Porter and Mervyn S. Jaswon and E. R. Huehns and Charles Anthony East and Jonathan W P Hazell},
  journal={British journal of haematology},
  year={1989},
  volume={73 3},
  pages={403-9}
}
Forty-seven patients with thalassaemia have been studied to define risk factors for development of sensorineural hearing loss, and to establish guidelines for safe chelation. Sensorineural hearing loss was only present in patients who had previously received desferrioxamine (DFO). The two most significant risk factors were the maximum dose of DFO previously received (P less than 0.01), and a serum ferritin of less than 2000 micrograms/l at that time (P less than 0.001). A therapeutic index… CONTINUE READING